AI-generated summary
Researchers tested transcranial photobiomodulation, a form of red or near-infrared light therapy, in a transgenic rat model of Alzheimer's disease at an early stage. Treated animals showed less anxious-depressive-like behavior than untreated AD animals, along with reduced neuronal damage, apoptosis, neuroinflammation and oxidative stress, according to the authors. The authors note this was an animal study, so findings may not apply to people.
- Who or what was studied
- TgF344 transgenic rats modeling early-stage Alzheimer's disease (wild-type, AD with sham PBM, and AD with PBM groups)
- Limits stated in the abstract
- The study was conducted in an animal model, and the abstract does not report the number of animals per group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Energy density (fluence)
- 3 J/cm2
- Power density (irradiance)
- 25 mW/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Neuroinflammation, Oxidative stress, Depression, Anxiety, Mitochondria, Irradiance. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.